June 6, 2013. We are disappointed that the FDA continues to waste their limited resources reopening what should be a closed case. If you are not ready to make that recommendation, then please keep the current safeguards in place.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Coalition Comments to FDA: Don’t Need a New Pathway for Antibiotics for Limited Populations!
January 30, 2013. The FDA considered a new way to approve drugs for use in small patient populations. NRC warn that such a pathway would put patients at risk of harm by giving them poorly studied drugs without knowing if the drugs provide any benefit.
Read More »NCHR Testimony before the FDA Advisory Committee Regarding Belsomra (Suvorexant)
May 22, 2013. We need to get a better sense of what the real benefits are, not just 5 minutes or 20 minutes more of uninterrupted sleep, but the actual functioning of a person on the next day.
Read More »NCHR Testimony on Nonthermal Shortwave Diathermy Devices Classification
May 21, 2013. Testimony of Caitlin Kennedy, senior fellow, on nonthermal shortwave diathermy devices classification, FDA Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee, on May 21, 2013
Read More »Letter to Congressman Markey in Support of VALID Act About Compounding Pharmacies
May 22, 2013. As members of the Patient, Consumer, and Public Health Coalition, we strongly support the Verifying Authority and Legality in Drug (VALID) Compounding Act of 2013. This bill would significantly strengthen FDA oversight of compounding pharmacies and help ensure patients get safe and effective life-saving medical products.
Read More »